肾炎康复片治疗原发性局灶节段硬化肾小球肾炎的临床观察

Abstract
Figure/Table
References (16)
Related Citation (2)

Download: PDF (0 KB) HTML (38 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the effect of Shenyankangfu Tablets in treatment of patients with primary focal segemental glomerulosclerosis（FSGS）. Methods From June 2012 to July 2014，61 patients diagnosed as primary FSGS in our hospitalwere divided into treatmentgroup（31 cases）and control group（30 cases）according to the order of diagnosis. Patientsin the treatmentgroupwere treatedwith Shenyankangfu Tabletsbased on routine doseofBenazaprilor Telmisartan，5 tablets/time，3 times/d，while patients in the control group were treated with　conventional dose of Benazapril or Telmisartan.Results Urine protein value in 24 hours after treatment in the treatment group was　（1079±843）mg，improved greatly than（1840±976）mg in the control group，and the difference was statistically significant（P＜0.01）；urine protein value in 24 hours in the treatment group after treatmentwas significantly reduced than that before treatment，and the differencewas statistically significant（P＜0.01）.The total effective rate in the treatment group was 87.1%，higher than 63.3%in the control group（P＜0.01）.Conclusion Shenyankangfu Tablets is effective in treatment of primary FSGS.

Key words： Shenyankangfu Tablets Focal segemental glomerulosclerosis Primary glomerulonephritis Chronic glomerulonephritis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GAO Cong-pu
	BAIShou-jun
	ZHU Ying-chun

Cite this article:

GAO Cong-pu,BAIShou-jun,ZHU Ying-chun. Clinical observasion of Shenyankangfu Tablets in treatment of patients with focal segemental glomerulosclerosis[J]. 中国当代医药, 2016, 23(29): 54-56.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I29/54

［1］	Fogo AB.Causesand pathogenesisof focalsegmentalglomerulosclerosis［J］.Nat Rev Nephrol，2015，11（2）：76-87.
［2］	Kou J，Wu J，YangHT，etal.Efficacyandsafetyofshenyankangfu tablets for primary glomerulonephritis：study protocol for randomized controlled trial［J］.Trials，2014，15：479-487.
［3］	邓跃毅，陈以平，唐红，等.肾炎康复片治疗糖尿病肾病的疗效观察［J］.中国中西医结合肾病杂志，2005，6（3）：151-153.
［4］	刘立纲，周太光，卢昌碧.小儿紫癜性肾炎180例临床分析［J］.华西医学，2009，24（2）：351-352.
［5］	刘宝厚，许筠.慢性肾小球肾炎的诊断、辨证分型及疗效判定（试行方案）［J］.上海中医药杂志，2006，40（6）：8-9.
［6］	王磊，丧大华.注射用阿魏酸钠联合氯沙坦治疗老年慢性肾小球肾炎的疗效［J］.中国老年学杂志，2013，2（33）：935-936.
［7］	陈灏珠，钟南山，陈江华.内科学［M］.8版.北京：人民卫生出版社，2013：524-525.
［10］	Mallat SG，Itani HS，Abou-Mrad RM，et al.Rituximab use in adult primary glomerulopathy：where is the evidence？［J］. Ther Clin Risk Manag，2016，12：1317-1327.
［11］	Filippone EJ，Dopson SJ，Rivers DM，et al.Adrenocorticotropic hormone analog use for podocytopathies［J］.IntMed Case Rep J，2016，9：125-133.
［13］	Clark WF，Huang SS，Walsh MW，et al.Plasmapheresis for the treatment of Kidney diseases［J］.Kidney Int，2016.［Epub ahead of print］.
［8］	Ren H，Shen P，Li X，et al.Tacrolimus versus cyclophosphamide insteroid-dependent or steroid-resistant focal segmental glomerulosclerosis：a randomized controlled trial［J］. Am JNephrol，2013，37（1）：84-90.
［9］	KittanamongkolchaiW，Cheungpasitporn W，Zand L.Efficacy and safety of adrenocorticotropic hormone treatment in glomerular diseases：a systematic review and meta-analysis ［J］.Clin Kidney J，2016，9（3）：387-396.
［12］	Fermandez-Juarez G，Villacorta J，Ruiz-Roso G，et al.Therapeutic variability in adultminimal change disease and focal segmental glomerulosclerosis［J］.Clin Kidney J，2016，9 （3）：381-386.
［14］	徐亚清.肾炎康复片治疗乙肝病毒相关性肾炎疗效观察［J］.中国社区医师（医学专业半月刊），2008，12（10）：88-90.
［15］	夏瑗瑜，李相友，张野，等.肾炎康复片联合来氟米特治疗尿检异常型IgA肾病的临床研究［J］.中国中西医结合肾病杂志，2008，9（9）：802-804.
［16］	Bose B，Cattran D.Glomerular diseases：FSGS［J］.Clin JAm Soc Nephrol，2014，9（3）：626-632.